| Literature DB >> 30733536 |
Yoriko Nonomura1,2, Seishiro Sawamura1, Ken Hanzawa3, Takashi Nishikaze4, Sadanori Sekiya4, Taiga Higuchi1, Fumiaki Nin1,5, Satoru Uetsuka6, Hidenori Inohara6, Shujiro Okuda7, Eiji Miyoshi8, Arata Horii2, Sugata Takahashi2, Shunji Natsuka3, Hiroshi Hibino9,10,11.
Abstract
Membrane proteins (such as ion channels, transporters, and receptors) and secreted proteins are essential for cellular activities. N-Entities:
Mesh:
Substances:
Year: 2019 PMID: 30733536 PMCID: PMC6367448 DOI: 10.1038/s41598-018-38079-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Isolation of the stria vascularis. (a) Structure of the cochlea. An overview image and cross-section of this organ are shown in left and right panels, respectively. In the latter, electrochemical properties of endolymph and perilymph are indicated. StV; stria vascularis, SL; spiral ligament, LW; lateral cochlear wall. (b–d) Dissociation of StV. The cochlea was dissected from the temporal bone (b) and divided sagittally into two parts along the cochlear axis (c). The StV was identified by brown pigmentation of the intermediate cells. Then, as shown in (d), the StV was carefully peeled away from the SL with a fine needle (see Methods).
Figure 2Verification of purity of the stria vascularis in the samples. (a) Cellular components of the lateral wall. The stria vascularis (StV) is composed of marginal, intermediate, and basal cells, whereas the spiral ligament (SL) consists of fibrocytes. This scheme was adapted from our earlier work[57]. (b) Assessment of purity of the StV in the obtained samples. qPCR analyses were performed separately on the StV (green bars) and SL (yellow bars) isolated from the lateral cochlear wall. In these assays, the primers for genes encoding K+,Cl−-cotransporter type 3 (KCC3) and Brn-4, which are exclusively expressed in SL, and those for barttin and claudin 11, which are specific to StV, were used. Quantitative data (n = 3) were collected with reference to an internal gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH); averages, standard errors, and P values determined by two-tailed Student’s t test are also shown.
Figure 3The workflow for characterisation of strial glycans. (a) An overview flowchart of the experiments conducted in this study. As the first step, glycans obtained from the stria vascularis were sequentially fractionated by three different HPLC types described in the orange box (upper left). The elution times recorded in reversed-phase and size fractionation HPLCs represent R and S values (Rstria and Sstria), respectively[29,32] (blue box). In parallel, the original samples extracted via reversed-phase HPLC were analysed by positive ion mode LC-ESI-MS and MS2 (green box in the upper right); the spectra provided monosaccharide composition and linkage patterns. On the basis of these data, of the HPLC analyses of 194 standard glycans[7,28], and of the empirical additivity rule[7], we predicted set(s) of Rstd and Sstd values or those of Rcalc and Scalc values for each glycan (pink box). A comparison between this information and the values of Rstria and Sstria determined the structures of some glycan species (the deep-blue-filled ellipse). The other glycans whose structures were not completely determined by this procedure (the pale-blue-filled ellipse) were next subjected to SALSA and positive ion mode MALDI-MS (dark-purple box). This experiment revealed the sialyl linkage patterns of the majority of the analysed glycans (the pale-blue-filled ellipse). Nevertheless, characterisation of the sialyl linkage in A3-13 required a series of more complicated analyses consisting of SALSA and negative ion mode MALDI-MSn (pale-purple box). DEAE: diethylaminoethyl, HPLC: high performance liquid chromatography, LC-ESI: liquid chromatography with electrospray ionisation, MS: mass spectrometry, Rstd: R value of standard glycans, Sstd: S value of standard glycans, Rcalc: calculated R value, Scalc: calculated S value, SALSA: sialic-acid-linkage–specific alkylamidation, MALDI: matrix-assisted laser desorption/ionisation. (b) The numbers of strial glycans extracted or characterised by each series of the methods described in (a). The methods are shown on the left side. Of 107 glycans collected by reversed-phase HPLC, each of the 19 species marked by a single hash tag (#) was detected as a fraction whose peak area was less than 2% of that of the N-5 fraction in the subsequent HPLC chromatogram, and therefore each was excluded from further assays (see text). Glycans indicated by a double hash tag (##) were likely to be O-linked-type or non-specific moieties (see text). Groups highlighted in deep blue have glycans whose structures were determined perfectly, whereas groups coloured with pale blue consist of glycans whose partial linkages were assigned temporarily or those whose linkages were not completely clarified after the analyses. In summary, the structures of 79 strial N-glycans in total were profiled, as indicated by the black bar. Details of the experiments for A3-13 and A3-18 species are described in the main text. *Sialylated species that have glycosidic linkages inaccessible to the analyses using R and S values. **Species that were initially identified as a single sialylated glycan but later found to have an additional sialyl linkage isomer.
Figure 4Separation and identification of N-glycans from the stria vascularis. (a) An elution profile of diethylaminoethyl (DEAE) anion exchange HPLC. Samples extracted from the stria vascularis were analysed by chromatography. Peaks of compounds without sialylation (class N) and with a modification consisting of one to four sialic acid residues (classes A1 to A4) were detected. A signal between N and A1 peaks derived from non-glycan fluorescent materials[7,28]. (b) An elution profile of reversed-phase HPLC. We analysed the fractions isolated by DEAE chromatography [N and A1–A4; see (a)]. The numbers point to significant peaks (for the criterion, see Results). The traces marked by dashed red boxes in panels A1 and A2 are expanded in insets. Numerous peaks within the initial ~10 min were likely to contain chemical reagents including pyridylamine and its derivatives[28].
Structures of N-glycans in the stria vascularis.
| Fraction No. | Rstria | Sstria | Rstd or | Sstd or | Relative amount | Assigned structure | |
|---|---|---|---|---|---|---|---|
| N | 1 | 31.757 | 8.37 |
|
| 27.1 | Man8GlcNAc2:(M8) |
| 2 | 33.304 | 7.51 |
|
| 12.8 | Man7GlcNAc2:(M7) | |
| 3 | 35.137 | 9.05 |
|
| 32.3 | Man9GlcNAc2:(M9) | |
| 4-1 | 38.140 | 7.46 |
|
| 10.4 | Man7GlcNAc2:(M7) | |
| 4-2 | 38.140 | 8.21 |
|
| 3.0 | Man8GlcNAc2:(M8) | |
| 5 | 40.152 | 6.64 |
|
| 100.0 | Man6GlcNAc2:(M6) | |
| 6-1 | 42.858 | 3.15 |
|
| 7.7 | Man2GlcNAc2:(M2) | |
| 6-2 | 42.858 | 6.02 |
|
| 4.0 | GlcNAcMan5GlcNAc2:(GnM5) | |
| 7-1 | 43.755 | 4.11 |
|
| 9.0 | Man3GlcNAc2:(M3) | |
| 7-2 | 43.755 | 5.01 |
|
| 5.2 | Man4GlcNAc2:(M4) | |
| 8-1 | 45.266 | 5.80 |
|
| 67.2 | Man5GlcNAc2:(M5) | |
| 8-2 | 45.266 | 7.30 |
|
| 4.2 | Man7GlcNAc2:(M7) | |
| 8-3 | 45.266 | 9.67 |
|
| 2.9 | GluMan9GlcNAc2:(G1M9) | |
| 10 | 49.780 | 6.48 | 2.0 | Ac-Man9GlcNAc2:(Ac-M9) | |||
| 11-1 | 51.191 | 4.87 |
|
| 2.4 | GlcNAc2Man3GlcNAc2:(AG12) | |
| 12-1 | 52.739 | 3.55 |
|
| 8.0 | Man2FucGlcNAc2:(M2F6) | |
| 12-2 | 53.507 | 4.45 |
|
| 10.0 | Man3FucGlcNAc2:(M3F6) | |
| 12-3 | 53.507 | 5.61 |
|
| 11.5 | GlcNAc2Man4GlcNAc2:(GnM4Bs) | |
| 14-2 | 55.595 | 6.31 |
|
| 7.7 | Gal2GlcNAc2Man3GlcNAc2:(BI) | |
| 15 | 56.807 | 4.89 | 3.7 | Ac-Man6GlcNAc2:(Ac-M6) | |||
| 16-1 | 58.699 | 5.62 | 2.1 | Ac-Man5GlcNAc2:(Ac-M5) | |||
| 16-2 | 58.699 | 6.48 | 2.0 | GalGlcNAcHexNAc3Man3GlcNAc2:(Hex4HexNAc6) | |||
| 17 | 59.934 | 5.12 |
|
| 2.2 | GlcNAc2Man3FucGlcNAc2:(AG12F6) | |
| 20 | 64.501 | 5.17 |
|
| 3.9 | GlcNAc2Man3FucGlcNAc2:(AG2BsF6) | |
| 21-1 | 66.000 | 5.16 |
|
| 17.8 | GlcNAc3Man3GlcNAc2:(AG12Bs) | |
| 21-2 | 66.000 | 7.39 | 2.3 | Gal2GlcNAc2HexNAc2Man3FucGlcNAc2:(Hex5HexNAc6dHex) | |||
| 22-1 | 68.153 | 5.80 |
|
| 5.6 | GalGlcNAc3Man3GlcNAc2:(BIBs-G2) | |
| 22-2 | 68.153 | 6.69 | 3.4 | GalGlcNAc4Man3FucGlcNAc2:(TEF6-3G) | |||
| 25 | 76.047 | 5.38 |
|
| 12.8 | GlcNAc3Man3FucGlcNAc2:(AG12BsF6) | |
| 26 | 78.263 | 5.97 |
|
| 6.9 | GalGlcNAc3Man3FucGlcNAc2:(BIBsF6-G1) | |
| 27 | 79.883 | 6.65 |
|
| 2.6 | Gal2GlcNAc3Man3FucGlcNAc2:(BIBsF6) | |
| A1 | 2 | 53.324 | 5.83 |
|
| 6.5 | NeuAcGalGlcNAcMan3GlcNAc2:(6N-MO1) |
| 3-1 | 54.312 | 6.47 |
|
| 26.9 | NeuAcGalGlcNAcMan4GlcNAc2:(6N-LnM4) | |
| 3-2 | 54.312 | 7.24 |
|
| 55.8 | NeuAcGalGlcNAcMan5GlcNAc2:(6N-LnM5) | |
| 4-1 | 58.874 | 6.03 |
|
| 3.0 | NeuAcGalGlcNAcMan4GlcNAc2:(3N-LnM4) | |
| 4-2 | 58.874 | 6.74 |
|
| 9.0 | NeuAcGalGlcNAcMan5GlcNAc2:(3N-LnM5) | |
| 5 | 59.998 | 6.05 |
|
| 4.1 | NeuAcGalGlcNAc2Man3GlcNAc2:(06N-BI-G2) | |
| 6 | 61.064 | 8.07 |
|
| 2.4 | NeuAcGal3GlcNAc3Man3FucGlcNAc2:(06N-TRF6) | |
| 8-1 | 62.732 | 6.06 |
|
| 4.6 | NeuAcGalGlcNAcMan3FucGlcNAc2:(6N-MO1F6) | |
| 8-2 | 62.732 | 6.71 |
|
| 9.9 | NeuAcGalGlcNAcMan4FucGlcNAc2:(6N-LnM4F6) | |
| 8-3 | 62.732 | 7.42 |
|
| 3.1 | NeuAcGalGlcNAcMan5FucGlcNAc2:(6N-LnM5F6) | |
| 9 | 64.148 | 5.96 |
|
| 2.8 | NeuAcGalGlcNAc2Man3GlcNAc2:(03N-BI-G2) | |
| 11 | 67.625 | 5.89 |
|
| 2.5 | NeuAcGalNAcGlcNAc2Man3FucGlcNAc2: [06N-BI(mLdn1)F6-G2] | |
| 12 | 68.806 | 6.28 |
|
| 5.9 | NeuAcGalGlcNAc2Man3FucGlcNAc2:(06N-BIF6-G2) | |
| 13 | 70.422 | 6.93 |
|
| 4.0 | NeuAcGal2GlcNAc2Man3FucGlcNAc2:(06N-BIF6) | |
| 14-1 | 71.278 | 6.30 |
|
| 2.2 | NeuAcGalGlcNAc3Man3GlcNAc2:(06N-BIBs-G2) | |
| 14-2 | 71.278 | 7.61 |
|
| 2.7 | NeuAcGal3GlcNAc2Man3FucGlcNAc2:(06N-Gaβ42-BIF6) | |
| 17-1 | 75.313 | 6.02 |
|
| 2.2 | NeuAcGalGlcNAcMan3FucGlcNAc2:(6N-MO2F6) | |
| 17-2 | 75.313 | 6.49 |
|
| 2.8 | NeuAcGal2GlcNAc2Man3FucGlcNAc2:(30N-BIF6) | |
| 18 | 76.811 | 5.57 |
|
| 2.9 | NeuAcGalGlcNAcMan3FucGlcNAc2:(3N-MO2F6) | |
| 19 | 79.040 | 6.08 |
|
| 3.4 | NeuAcGalGlcNAc3Man3GlcNAc2:(60-BIBs-G1) | |
| 20 | 81.076 | 6.55 |
|
| 3.8 | NeuAcGalGlcNAc3Man3FucGlcNAc2:(06N-BIBsF6-G2) | |
| 21 | 84.022 | 7.10 |
|
| 3.4 | NeuAcGal2GlcNAc3Man3FucGlcNA2:(06N-BIBsF6) | |
| 22 | 86.338 | 6.29 |
|
| 5.9 | NeuAcGalGlcNAc3Man3FucGlcNAc2:(06-BIBsF6-G2) | |
| A2 | 14-1 | 71.510 | 7.11 |
|
| 21.9 | NeuAc2Gal2GlcNAc2Man3GlcNAc2:(66N-BI) |
| 14-2 | 71.510 | 7.83 | 2.1 | NeuAc2Gal3GlcNAc3Man3FucGlcNAc2:(dN-TRF6) | |||
| 15 | 73.106 | 6.68 |
|
| 4.8 | NeuAc2Gal2GlcNAc2Man3GlcNAc2:(36N-BI) | |
| 16-1 | 75.619 | 8.04 | 2.2 | NeuAc2Gal3GlcNAc4Man3FucGlcNAc2:(dN-TEF6-1G or dN-TRBsF6) | |||
| 16-2 | 75.619 | 8.61 | 3.4 | NeuAc2Gal4GlcNAc4Man3FucGlcNAc2:(dN-TEF6) | |||
| 17 | 76.989 | 6.89 |
|
| 8.1 | NeuAc2GalGalNAcGlcNAc2Man3FucGlcNAc2: [66N-BI(mLdn1)F6] | |
| 18 | 77.890 | 7.32 |
|
| 19.2 | NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(66N-BIF6) | |
| 19 | 79.027 | 6.60 |
|
| 2.7 | NeuAc2Gal2GlcNAc2Man3FucGlcNAc2: [66N-BI(dLdn1,2)F6] | |
| 20 | 80.969 | 6.90 |
|
| 8.5 | NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(36N-BIF6) | |
| 23 | 85.992 | 6.54 |
|
| 5.0 | NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(33N-BIF6) | |
| 24 | 90.046 | 7.46 | 6.4 | NeuAc2Gal2GlcNAc3Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G) | |||
| 25 | 93.339 | 6.92 | 5.1 | NeuAc2Gal2GlcNAc3Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G) | |||
| 27 | 99.235 | 6.50 | 2.1 | NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G) | |||
| A3 | 10 | 77.082 | 8.11 | 2.9 | NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6) | ||
| 12 | 79.491 | 7.81 | 5.2 | NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6) | |||
| 13 | 81.419 | 5.59 | 2.8 | SO3−-NeuAcGalNAc2GlcNAc2Man3FucGlcNAc2: [SO3−6N-BI(dLdn1,2)F6] | |||
| 14 | 82.500 | 7.40 | 2.9 | NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6) | |||
| 15-1 | 83.595 | 7.93 | 3.1 | NeuAc3Gal3GlcNAc3Man3GlcNAc2:(trN-TR) | |||
| 15-2-1 | 83.595 | 8.52 | 1.2 | NeuAc3Gal3GlcNAc4Man3FucGlcNAc2:(trN-TRBsF6 or trN-TEF6-1G) | |||
| 15-2-2 | 83.595 | 8.52 | 2.7 | NeuAc3Gal3GlcNAc4Man3FucGlcNAc2:(trN-TRBsF6 or trN-TEF6-1G) | |||
| 15-3-1 | 83.595 | 8.95 | 1.5 | NeuAc3Gal4GlcNAc4Man3FucGlcNAc2:(trN-TEF6) | |||
| 15-3-2 | 83.595 | 8.95 | 1.6 | NeuAc3Gal4GlcNAc4Man3FucGlcNA2:(trN-TEF6) | |||
| 18 | 90.797 | 8.05 | 7.6 | NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6) | |||
| A4 | 6 | 88.863 | 8.88 | 2.1 | NeuAc4Gal4GlcNAc4Man3FucGlcNAc2:(teN-TEF6) | ||
| 7 | 90.864 | 8.54 | 2.2 | NeuAc4Gal4GlcNAc4Man3FucGlcNAc2:(teN-TEF6) | |||
Possible structures and names of individual 79 N-glycans identified in the present study are listed with the R and S values of the strial samples (Rstria and Sstria), the R and S values of the standard glycans (Rstd and Sstd: Bold) or those calculated based on empirical additivity rule and MS data of the strial glycan (Rcalc and Scalc: Italic) and relative amounts [toward the amount of N-5 (Man6GlcNAc2, i.e. M6)]. Following data are described in Supplementary Table S2; peak areas of the glycan fractions obtained by size fractionation HPLC, total peak intensity of A3-15-2-1, A3-15-2-2, A3-15-3-1, and A3-15-3-2 in positive ion mode MALDI-QIT-TOF-MS analysis, the m/z values detected in LC-ESI-MS spectrum, the m/z values described in mass databases, the ion types detected in LC-ESI-MS analysis and symbolic images of the glycan structures.
Figure 5Structural analyses of A1-3-2 and A1-4-2 glycans. (a,b) Left panels illustrate full-scan mass spectra (m/z range: 500–2000) with A1-3 and A1-4 fractions eluted via reversed-phase HPLC (see Fig. 4b). Right panels depict signals of A1-3-2 and A1-4-2 analysed in MS2 mode. In these and subsequent spectra, symbolic notation above the peaks indicates the composition and linkage patterns of the products. Annotated structure of the glycans NeuAcGalGlcNAcMan5GlcNAc2 (mN-LnM5) is also shown in the left panels. (c) Comparison of R and S values obtained in the analyses of the strial glycans with three different HPLCs (Rstria and Sstria for A1-3-2 and A1-4-2 species) to those of standard glycans (Rstd and Sstd) of 6N-LnM5 and 3N-LnM5 (Supplementary Table S4). These R and S values are indicated in parentheses. Shown in the table are error Rstd and Sstd factors in each pair. Procedures to obtain all the values and factors are described in the main text. The results highlighted in red satisfy the criterion of the glycan assignment (<5; see text). (d) Determined structures of A1-3-2 and A1-4-2 glycans. PA: pyridylamine.
Figure 6Determination of A1-8-1 glycan structure. (a) Mass spectra of A1-8-1 species. The profile of the A1-8 fraction analysed by mass spectrometry (MS) is shown in the left panel. The analysed fraction was isolated by reversed-phase HPLC (see Fig. 4b). Strial glycan A1-8-1 was detected as the signal at m/z 896.59 [M + 2 H]2+, and this fragment was next assayed with MS2 as displayed in the right panel. In both panels, monosaccharide composition and possible glycosidic linkage patterns for each product and annotated structure of A1-8-1 [NeuAcGalGlcNAcMan3FucGlcNAc2 (mN-MOF6)] are illustrated with symbols. (b,c) Characterisation of the structure of the A1-8-1 glycan. R and S values obtained through the analysis of the strial glycans with three different HPLCs (Rstria and Sstria) were compared with R and S values of standard glycans (Rstd and Sstd) 3N-MO1F6 and 3N-MO2F6 (Supplementary Table S4). (b) as well as calculated R and S values of 6N-MO1F6 and 6N-MO2F6 (Rcalc and Scalc) (c). The R and S values are shown in parentheses. Error Rstd and Sstd factors and error Rcalc and Scalc factors in each pair were obtained, and the results are depicted in the tables in (b) and (c). Procedures for obtaining all the values and factors are described in the main text. The results indicated in red meet the criterion of the glycan assignment (<5; see text). (d) The candidate structure for A1-8-1 species. PA: pyridylamine.
Figure 7Characterisation of A2-24 glycan structure with sialic acid derivatisation. (a) Mass spectra of A2-24 species. The left panel shows the result of LC-ESI mass spectrometry (MS) analysis of the A2-24 fraction isolated by reversed-phase HPLC (see Fig. 4b). The product detected as a peak at m/z 1326.12 [M + 2 H]2+ was subjected to MS2 analysis and separated into several fragments as illustrated in the right panel. Constituents and possible linkage patterns for some products are also illustrated with symbols. NeuAc2Gal2GlcNAc3Man3FucGlcNAc2 (dN-BIBsF6 or dN-TRF6-1G) is annotated structure of strial glycan A2-24 (left panel). Note that the peak at m/z 884.63 in the left panel represents tri-protonated form [M + 3 H]3+ of the A2-24 glycan. (b) A full-scan positive ion mode MALDI-QIT-TOF mass spectrum (m/z > 2000) of the A2-24 fraction with sialic-acid-linkage–specific alkylamidation (SALSA). The strong signal at m/z 2755.11 [M + Na]+ represents the derivatised A2-24 species. The dotted line denotes the predicted position of the non-alkylamidated A2-24 glycan in sodiated form [M + Na]+ on the basis of its calculated m/z value (2672.97 marked by ‘Pre SALSA’). The difference in molecular mass between these two signals is shown (82.14 Da). (c) Assigned structure of the A2-24 strial glycan. Note that the linkage patterns among three N-acetylglucosamine residues in antenna structures and two mannose residues in the core structure have yet to be determined. PA: pyridylamine.
Figure 8Analysis of A3-13 glycan structure with SALSA and multiple mass spectrometry modes. (a) A positive ion mode MALDI-QIT-TOF mass spectrum of A3-13 species. The sample analysed in this experiment was obtained by reversed-phase HPLC and derivatised with SALSA (see Supplementary Fig. S3). (b,c) Negative ion mode MALDI-QIT-TOF MS spectra of the reversed-phase HPLC fraction containing A3-13 species. The data on the samples without and with SALSA are displayed in panels b and c, respectively. In (b), the peaks at m/z 2316.8 [M-H]− and at m/z 2338.8 [M-H]− represent a deprotonated ion of the A3-13 strial glycan and its Na+-bound form, respectively, whereas the moiety (of the former) deficient in an acidic functional group is observed as a signal at m/z 2236.9 [M-H]−. Note that the deprotonated glycan (b) shifted by 41.1 Da with SALSA (c). (d) An MS2 spectrum of SALSA-derivatised A3-13 glycan isolated by the MS assay (a peak at m/z 2357.9 [M-H]− in (c). A signal at m/z 2025.7 [M-H]− should result from neutral loss of a single isopropylamine (iPA)-bound sialic acid in the parent ion. The lack of one and two HexNac residues likely produced two fractions at m/z 1822.6 [M-H]− and 1619.6 [M-H]−, respectively. (e) Data from the MS3 analysis of the product at m/z 1619.6 [M-H]− in MS2 mode. The signal at m/z 1174.3 [M-H]− stems from loss of the pyridylamine (PA)-bound GlcNAc and Fuc in the parent ion. The difference in m/z between this signal and other two peaks (m/z 971.2 [M-H]− and m/z 485.1 [M-H]−) can be explained by a loss of HexNAc or a loss of both HexNAc and three Hex residues, respectively, as shown in the panel. As described in the main text, the fraction at m/z 485.1 [M-H]− consists of GalNAcGlcNAc modified by a sulphate group. (f) The MS4 spectrum obtained from the parent ion detected as a signal at m/z 485.1 [M-H]− in MS3 mode. Difference in m/z value between the parent ion and the product at m/z 282.0 [M-H]− corresponds to the m/z value of a HexNAc residue. Composition of the moiety should be sulphated GalNAc or GlcNAc (see symbolic notations). (g) Possible structure of A3-13. This glycan has two GalNAc residues; however, which one is attached with a sialic acid or a sulphate group remains to be determined. (h) Mass spectra of A3-13 species (see also Supplementary Fig. S2). The left panel shows the result of LC-ESI MS analysis with the A3-13 fraction isolated through reversed-phase HPLC (see Fig. 4b). The fragment at m/z 1160.3 [M + 2 H]2+ was next subjected to a surgical MS2 assay, and the result is shown in right panel. Constituents and possible linkage patterns described above several peaks in both panels are based on the conclusion that A3-13 strial glycan is sulphated NeuAcGalNAc2GlcNAc2Man3FucGlcNAc2 [SO3−-6N-BI(dLdn1,2)F6] (see g). PA: pyridylamine.
Figure 9A profile of N-glycans in stria vascularis. Strial 79 N-glycan types determined by the workflow shown in Fig. 3 are listed in (a). In this panel, the amount of each glycan was normalised to that of N-5 (Man6GlcNAc2, i.e. M6), which is the most abundant among all the glycan species. Yellow, orange, blue, and green bars indicate paucimannose, high-mannose, complex, and hybrid type glycans. Structure of the glycan marked by black bar belongs to either complex or hybrid type (see text). Data on these 79 glycans are derived from Table 1 and Supplementary Tables S1 and S2. The numbers of sialic acid residues attached to glycans are also shown below the names. Pie graphs in (b–d) describe populations of paucimannose (yellow), high-mannose (orange), complex (blue), and hybrid (green), and hybrid or complex type (black) glycans (b) and proportions of sialylated (purple) and core-fucosylated (red) glycans (c and d, respectively). For comparison, the proportion of each of the four glycan types (see b) is also shown at the edges of graphs (c and d).